RNA-targeting small molecules: a new frontier of drug discovery
Historically, drug discovery has centred around proteins but as targets become increasing saturated, novel RNA-targeting drugs indicate potential…
This Pharma Giant Is Using AI to Dominate Drug Discovery
There’s no denying modern-day artificial intelligence (AI) is doing some pretty cool stuff. But, to say it’s been…
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
By Kamal Choudhury Feb 9 (Reuters) – Privately held Iambic said on Monday it has entered a multi-year…
Marty Makary addresses staff concerns over drug voucher program
WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Synthetic Cannabinoid Comes Without the Side Effects
Northeastern University researchers have made a breakthrough drug discovery, developing the first synthetic endogenous cannabinoid compound, with repercussions…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
Countries used to test drugs often don’t see the approved medicines, study finds
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…
AbbVie parts ways with Calico
Unexpected uncoupling raises questions about the pace – and patience – of longevity drug discovery amid shifting pharma…
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…